Provided by Tiger Fintech (Singapore) Pte. Ltd.

AbCellera Biologics

4.24
+0.12002.91%
Pre-market: 4.980.7400+17.45%04:40 EDT
Volume:8.57M
Turnover:35.45M
Market Cap:1.27B
PE:-7.47
High:4.26
Open:4.13
Low:4.03
Close:4.12
52wk High:5.82
52wk Low:1.89
Shares:298.48M
Float Shares:202.40M
Volume Ratio:1.92
T/O Rate:4.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5679
EPS(LYR):-0.5533
ROE:-15.59%
ROA:-12.94%
PB:1.24
PE(LYR):-7.66

Loading ...

Stock Track | AbCellera Biologics Soars 17.69% Pre-Market on Stellar Q2 Earnings, Revenue Triples Estimates

Stock Track
·
37 mins ago

Stock Track | AbCellera Biologics Surges 17.69% Pre-Market on Stellar Q2 Earnings, Revenue Triples Estimates

Stock Track
·
37 mins ago

Stock Track | AbCellera Biologics Soars 18.63% as Q2 Revenue Triples, Beating Estimates

Stock Track
·
8 hours ago

Canadian biotech firm AbCellera Q2 revenue beats estimates

Reuters
·
10 hours ago

AbCellera Biologics Reports Q2 2025 Financial Results

TIPRANKS
·
11 hours ago

Stock Track | AbCellera Biologics Soars 6.13% After-Hours on Strong Q2 Earnings Beat

Stock Track
·
12 hours ago

Stock Track | AbCellera Biologics Soars 6.13% After-Hours on Strong Q2 Earnings Beat

Stock Track
·
12 hours ago

AbCellera Q2 Revenue USD 17.1 Million Vs. IBES Estimate USD 6.12 Million

Reuters
·
12 hours ago

AbCellera Biologics Q2 EPS $(0.12) Beats $(0.15) Estimate, Sales $17.084M Beat $5.824M Estimate

Benzinga
·
12 hours ago

AbCellera Biologics Is Maintained at Overweight by Keybanc

Dow Jones
·
Jul 14

Abcellera Biologics Inc. to Announce Second Quarter 2025 Financial Results

Reuters
·
Jul 08

AbCellera Biologics Coverage Assumed by Leerink Partners at Outperform

Dow Jones
·
Jul 07

Village Farms International And 2 Other Promising Penny Stocks For Your Watchlist

Simply Wall St.
·
Jul 05

AbCellera Biologics Inc. Concluded Annual Shareholders Meeting

Reuters
·
Jun 14

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Motley Fool
·
Jun 03

AbCellera Biologics Receives Health Canada Approval for Trial

TIPRANKS
·
May 31

AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Clinical Trial of Atopic Dermatitis Treatment ABCL575

Reuters
·
May 31

AbCellera Biologics Is Maintained at Buy by Truist Securities

Dow Jones
·
May 17

Truist Financial Remains a Buy on AbCellera Biologics (ABCL)

TIPRANKS
·
May 16

AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment

MT Newswires Live
·
May 15